MA50504A - Composés antibactériens - Google Patents
Composés antibactériensInfo
- Publication number
- MA50504A MA50504A MA050504A MA50504A MA50504A MA 50504 A MA50504 A MA 50504A MA 050504 A MA050504 A MA 050504A MA 50504 A MA50504 A MA 50504A MA 50504 A MA50504 A MA 50504A
- Authority
- MA
- Morocco
- Prior art keywords
- antibacterial compounds
- antibacterial
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Warehouses Or Storage Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1718285.8A GB201718285D0 (en) | 2017-11-03 | 2017-11-03 | Antibacterial Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50504A true MA50504A (fr) | 2020-09-09 |
Family
ID=60664899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050504A MA50504A (fr) | 2017-11-03 | 2018-11-02 | Composés antibactériens |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11345694B2 (fr) |
| EP (1) | EP3704105B1 (fr) |
| JP (2) | JP7348897B2 (fr) |
| KR (1) | KR102470319B1 (fr) |
| CN (1) | CN111566099B (fr) |
| AU (1) | AU2018361828B2 (fr) |
| BR (1) | BR112020008531A2 (fr) |
| CA (1) | CA3081423A1 (fr) |
| CL (2) | CL2020001147A1 (fr) |
| CO (1) | CO2020005420A2 (fr) |
| EA (1) | EA202091118A1 (fr) |
| GB (1) | GB201718285D0 (fr) |
| GE (1) | GEP20237522B (fr) |
| IL (1) | IL274229B2 (fr) |
| MA (1) | MA50504A (fr) |
| MX (2) | MX2020004562A (fr) |
| NZ (1) | NZ764310A (fr) |
| PE (2) | PE20221006A1 (fr) |
| SG (1) | SG11202003717UA (fr) |
| UA (1) | UA128475C2 (fr) |
| WO (1) | WO2019086890A1 (fr) |
| ZA (1) | ZA202002093B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| EP3781561B1 (fr) | 2018-04-18 | 2024-03-13 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN111635372B (zh) * | 2020-06-28 | 2022-05-27 | 齐鲁工业大学 | 一种恶唑酮衍生物及其合成方法 |
| EP4333854A1 (fr) * | 2021-05-03 | 2024-03-13 | Discuva Ltd. | Composé antibactérien |
| TW202340531A (zh) | 2022-02-21 | 2023-10-16 | 日商三井化學股份有限公司 | 金屬構件、金屬樹脂接合體及金屬構件之製造方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA869348B (en) | 1985-12-12 | 1987-10-28 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
| US4780470A (en) * | 1986-08-19 | 1988-10-25 | Smithkline Beckman Corporation | Inhibition of interleukin-1 by monocytes and/or macrophages |
| JP2808460B2 (ja) * | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
| JPH09124640A (ja) | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| CO5271680A1 (es) * | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| AU2003249977A1 (en) | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| JP2004196678A (ja) | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | ピラゾール系誘導体 |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| JP4853284B2 (ja) * | 2004-03-05 | 2012-01-11 | 大正製薬株式会社 | チアゾール誘導体 |
| JP2007277230A (ja) * | 2006-03-15 | 2007-10-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| EP2513064B1 (fr) * | 2009-12-17 | 2018-07-04 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Composé, compositions et procédés de lutte contre les biofilms |
| GB201016261D0 (en) | 2010-09-28 | 2010-11-10 | Univ Leuven Kath | Compounds for controlling biofilms and process for their production |
| WO2012135016A2 (fr) | 2011-03-25 | 2012-10-04 | North Carolina State University | Inhibition de biofilms bactériens et croissance microbienne avec des dérivés d'imidazole |
| RU2612958C2 (ru) * | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| US8840912B2 (en) | 2012-01-09 | 2014-09-23 | North Carolina State University | Imidazole derivatives useful for controlling microbial growth |
| KR102405136B1 (ko) | 2014-05-16 | 2022-06-07 | 아트리바 테라퓨틱스 게엠베하 | 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략 |
| MY186133A (en) | 2015-03-02 | 2021-06-24 | Rigel Pharmaceuticals Inc | Tgf-? inhibitors |
| WO2016141381A2 (fr) | 2015-03-05 | 2016-09-09 | University Of Notre Dame Du Lac | Potentialisateurs d'antibiotiques bêta-lactames |
| CA3030582A1 (fr) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Composes et leurs utilisations dans le traitement de cancers et d'autres etats medicaux |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
-
2017
- 2017-11-03 GB GBGB1718285.8A patent/GB201718285D0/en not_active Ceased
-
2018
- 2018-11-02 NZ NZ764310A patent/NZ764310A/en unknown
- 2018-11-02 PE PE2022000118A patent/PE20221006A1/es unknown
- 2018-11-02 PE PE2020000454A patent/PE20211390A1/es unknown
- 2018-11-02 CA CA3081423A patent/CA3081423A1/fr active Pending
- 2018-11-02 MX MX2020004562A patent/MX2020004562A/es unknown
- 2018-11-02 WO PCT/GB2018/053183 patent/WO2019086890A1/fr active Application Filing
- 2018-11-02 EP EP18800297.6A patent/EP3704105B1/fr active Active
- 2018-11-02 KR KR1020207015574A patent/KR102470319B1/ko active IP Right Grant
- 2018-11-02 AU AU2018361828A patent/AU2018361828B2/en active Active
- 2018-11-02 CN CN201880085171.5A patent/CN111566099B/zh active Active
- 2018-11-02 MA MA050504A patent/MA50504A/fr unknown
- 2018-11-02 EA EA202091118A patent/EA202091118A1/ru unknown
- 2018-11-02 JP JP2020524275A patent/JP7348897B2/ja active Active
- 2018-11-02 UA UAA202003341A patent/UA128475C2/uk unknown
- 2018-11-02 SG SG11202003717UA patent/SG11202003717UA/en unknown
- 2018-11-02 US US16/761,016 patent/US11345694B2/en active Active
- 2018-11-02 BR BR112020008531-6A patent/BR112020008531A2/pt unknown
- 2018-11-02 GE GEAP201815801A patent/GEP20237522B/en unknown
-
2020
- 2020-04-26 IL IL274229A patent/IL274229B2/en unknown
- 2020-04-30 CO CONC2020/0005420A patent/CO2020005420A2/es unknown
- 2020-04-30 CL CL2020001147A patent/CL2020001147A1/es unknown
- 2020-05-04 ZA ZA2020/02093A patent/ZA202002093B/en unknown
- 2020-07-13 MX MX2021010246A patent/MX2021010246A/es unknown
-
2021
- 2021-08-27 CL CL2021002263A patent/CL2021002263A1/es unknown
- 2021-11-01 JP JP2021178557A patent/JP2022025116A/ja not_active Withdrawn
-
2022
- 2022-04-25 US US17/728,335 patent/US20220372027A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42293A (fr) | Composés antibactériens | |
| MA49701A (fr) | Composés immunomodulateurs | |
| MA47131A (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| MA52948A (fr) | Composés | |
| MA51669A (fr) | Composés | |
| MA41614A (fr) | Composés antiviraux | |
| MA53003A (fr) | Composés | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| MA45221A (fr) | Nouveaux composés antibactériens | |
| DK4039675T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| MA50504A (fr) | Composés antibactériens | |
| DK3681282T3 (da) | Antimikrobiel belægning | |
| DK3387930T3 (da) | Stofanordning | |
| MA44020A (fr) | Composés antitumoraux | |
| MA49621A (fr) | Composés bifonctionnels | |
| MA49522A (fr) | Nouveaux composés de quinoléinone | |
| MA52946A (fr) | Composés | |
| MA51221A (fr) | Composés de pyrazolopyridinone | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| MA49885A (fr) | Composés macrocycliques | |
| MA49880A (fr) | Composés anticancéreux | |
| MA43791A (fr) | Composés de carbapénème | |
| DK3445766T3 (da) | Ny antimikrobiel forbindelse | |
| MA43799A (fr) | Composés de 2-oxindole | |
| MA41168A (fr) | Nouveaux composés antibactériens |